title: Reduction of systemic exposure and toxicity of cisplatin by encapsulation in poly-lactide-co-glycolide.
abstract: The tissue distribution and normal tissue toxicity of cisplatin (cDDP) administered as poly-lactide-co-glycolide (PLAGA) microspheres, developed for loco-regional administration of cDDP to the liver, were studied in Wag/Rij rats. Venoportal administration of this formulation resulted in a reduction in total systemic and renal toxicity, which correlated with a decrease in normal tissue exposure to cDDP while maintaining high liver platinum levels. Liver-to-kidney platinum level ratios were 28 times higher after 4 h and 19 times higher after 24 h with PLAGA-cDDP microspheres than with free cDDP. Liver-to-blood platinum ratios at these times were 38 times and 36 times higher using PLAGA-cDDP. In a CC531 colon carcinoma liver micrometastases model, cytotoxicity of microsphere-released cDDP was confirmed in vivo by equal inhibition of tumor growth by PLAGA-cDDP and free cDDP over a period of 26 days. Free cDDP, however, caused significantly more histological renal damage and total body weight loss. The results were supported by the finding of higher plasma creatinine and urea concentrations 26 days after administration of free cDDP. Kidney platinum levels were 7 times lower when PLAGA-cDDP was used. These findings indicate a sparing effect on normal tissues when cDDP is targeted to the liver by formulation in PLAGA. PLAGA-cDDP microspheres may, therefore, be a useful and effective addition to current techniques of loco-regional chemotherapy for disseminated hepatic tumors.
authors.affiliation: Division of Experimental Therapy, The Netherlands Cancer Institute, Amsterdam.
authors.forename: R
authors.initials: R
authors.lastname: Verrijk
authors.forename: I J
authors.initials: IJ
authors.lastname: Smolders
authors.forename: N
authors.initials: N
authors.lastname: Bosnie
authors.forename: A C
authors.initials: AC
authors.lastname: Begg
mesh_terms: D000818:Animals; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D004337:Drug Carriers; D008099:Liver / Q000378:metabolism*; D008113:Liver Neoplasms / Q000517:prevention & control; D008297:Male; D008863:Microspheres; D051381:Rats; D014018:Tissue Distribution
chemical_list: D004337:Drug Carriers; D002945:Cisplatin